Paola D'Ambrosio

Dr. Paola D'Ambrosio


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Genes
Verified
Journal Article
Open access
PDF file
CMCecilia Mancini
Cecilia Mancini
LCLuigi Chiriatti
Luigi Chiriatti
ABAlessandro Bruselles
Alessandro Bruselles
PDPaola D'Ambrosio
Paola D'Ambrosio
ACAndrea Ciolfi
Andrea Ciolfi
MTMarco Tartaglia
Marco Tartaglia
Background: Dominantly acting variants in TUBB2B have primarily been associated with cortical dysplasia complex with other brain malformations 7 (CDCBM7), a disorder in which cortical brain abnormalities are typically linked to developmental delay/intellectual disability (DD/ID) and seizures. While the majority of TUBB2B pathogenic variants have been linked to isolated CDCBM7, only one family with CDCBM7 and congenital fibrosis of the extraocular muscles (CFEOM) has been reported so far. We describe a second individual with a severe phenotype of CFEOM combined with CDCBM7 carrying a pathogenic TUBB2B missense variant previously reported in two individuals with isolated CDCBM7. Methods: A trio-based WGS analysis was performed. The structural impact of the identified substitution was assessed by using the UCSF Chimera (v.1.17.3) software and PyMOL docking plugin DockingPie tool. Results: WGS analysis identified a de novo missense TUBB2B variant (p.Ile202Thr, NM_178012.5), previously associated with isolated CDCBM7. Structural analysis and docking simulations revealed that Ile202 contributes to establishing a proper hydrophobic environment required to stabilize GTP/GDP in the β-tubulin pocket. p.Ile202Thr was predicted to disrupt these interactions. Conclusions: Our findings broaden the mutational spectrum of TUBB2B-related CFEOM, targeting a different functional domain of the protein, and further document the occurrence of phenotypic heterogeneity. We also highlight the limitations of exome sequencing in accurately mapping TUBB2B coding exons due to its high sequence homology with TUBB2A and suggest targeted or genome analyses when clinical suspicion is strong.

30 June 2026 in Genes
Verified
Journal Article
Open access
PDF file
LCLorenzo Cipriano
Lorenzo Cipriano
RPRoberta Petillo
Roberta Petillo
Manuela PrioloManuela Priolo
Manuela Priolo
PDPaola D'Ambrosio
Paola D'Ambrosio
Background: Adult-onset recessive cerebellar ataxias remain frequently unresolved after next-generation sequencing, partly because phenotype-driven filtering can deprioritize biallelic variants in genes historically associated with severe pediatric multisystem disease. This review examines how attenuated, hypomorphic, or residual-function genotypes may present as late-onset, cerebellar-predominant disease and aims to support clinical interpretation of apparently discordant recessive findings. Methods: We performed a narrative, pathway-based synthesis of autosomal recessive adult- or late-onset ataxia involving genes classically linked to lysosomal/neuronal ceroid lipofuscinosis and peroxisomal disorders. Reports were assessed for age at onset, cerebellar and extracerebellar chronology, variant class, zygosity, segregation/in-trans confirmation, biochemical or functional evidence, and implications for clinician–laboratory interpretation. Results: Published reports indicate that selected NCL-related and peroxisomal genes may be clinically relevant in adult-onset cerebellar ataxia, especially when accompanied by retinal disease, hearing loss, neuropathy, cognitive or psychiatric features, epilepsy/myoclonus, movement-disorder signs, or subtle biochemical abnormalities. Apparent phenotype–gene discordance may be compatible with residual function, allelic-series effects, and cerebellar selective vulnerability, although evidence is often limited to case reports or small series with variable segregation, biochemical, and functional support. We propose a workflow based on structured phenotype transfer, in-trans confirmation, targeted re-phenotyping, ACMG/AMP-informed evidence weighting, and avoidance of label-based exclusion from “ataxia gene” lists. Conclusions: Adult-onset recessive ataxia should not be interpreted only through canonical pediatric disease labels. A pathway-aware, phenotype-complete approach may reduce avoidable VUS retention and improve recognition of attenuated genetic presentations.

14 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
PDPaola D'Ambrosio
Paola D'Ambrosio
LCLorenzo Cipriano
Lorenzo Cipriano
APAlessia Pugliese
Alessia Pugliese
RPRoberta Petillo
Roberta Petillo
DRDario Ricciardi
Dario Ricciardi
Manuela PrioloManuela Priolo
Manuela Priolo
SCN4A encodes the skeletal-muscle voltage-gated sodium channel NaV1.4. Pathogenic variation in this gene produces fundamentally different disease mechanisms, including dominant alpha-pore gain of function, dominant S4 gating-pore currents, and reduced channel availability, with severe biallelic loss of function causing congenital myopathy and fetal hypokinesia. This heterogeneity makes variant interpretation difficult because formal variant classification, the direction of channel dysfunction, and patient-level disease attribution are closely related but distinguishable conclusions. In this review, we synthesize the clinical, genetic, electrophysiological, structural, and functional evidence relevant to SCN4A variant interpretation, with particular attention to missense variants of uncertain significance. We examine how inheritance, channel topology, phenotype, population data, segregation, RNA evidence, regional and residue-level context, and mechanism-matched functional assays can be integrated within the ACMG/AMP framework. Published pathogenic-enriched regions, gnomAD regional missense constraint, and same-residue observations may contribute to variant interpretation when the requirements of an applicable ACMG/AMP criterion are met; when they have not been specifically validated or calibrated for SCN4A, they are best used as contextual information to prioritize additional evidence generation. Based on this literature, we organize these evidence domains into a practical phenotype-first, mechanism-informed workflow for SCN4A variant interpretation. This workflow is not intended as an alternative to or extension of ACMG/AMP but as an SCN4A-specific application of established variant-interpretation principles in a gene associated with multiple inheritance patterns and directionally distinct disease mechanisms. After technical confirmation of a candidate variant, as well as phenotype and inheritance context guide selection of the relevant disease model, appropriately validated functional evidence may contribute directly to ACMG/AMP classification, while functional mechanism and patient-level disease attribution are documented as related but distinguishable interpretative outputs. The same approach applies when a variant is identified through genotype-first sequencing: interpretation should return to deliberate phenotyping, inheritance assessment, electrophysiological characterization, and consideration of the differential diagnosis before disease causality is inferred.